Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

NCT00068952 | Completed Phase 3

• 2 other identifiers: EDOAGL-8725-001A5921009
• Study Type: interventional
• Target: 118
• Locations: 12 countries
• Sites: 48

Brief Summary

The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.

Conditions

Glioblastoma

Outcome Measures

Primary Outcomes (1)

• To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy

Secondary Outcomes (1)

• To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin

Interventions

Edotecarin DRUG

Temozolomide DRUG

Carmustine (BCNU) DRUG

Lomustine (CCNU) DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)
• Must have past biopsy samples available for central pathology review
• Must have evidence on Gd-MRI of progressive/recurrent disease
• Must have measurable disease on Gd-MRI obtained within 14 days prior to start of study treatment
• Must be at least 18 years of age
• Must have a Karnofsky Performance Status score of at least 70
• If being treated with steroids, the steroid dose must be stable or decreasing for 1 week prior to randomization
• If being treated with anticonvulsants, must have no change in the type of anticonvulsants for 2 weeks prior to randomization
• All acute toxic effects (except for alopecia) of any prior treatment must have resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)
• Baseline laboratory data must be within the following limits: absolute neutrophil count at least 1500; platelets at least 100,000; hemoglobin at least 9.0 g/dL; serum creatinine no greater than 1.5 mg/dL, total serum bilirubin no greater than 1.5 times the upper limit of the normal range; SGOT and SGPT no greater than 2.5 times the upper limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test (for females of childbearing potential) negative within 7 days prior to start of study treatment
• At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at least 4 weeks since completion of prior temozolomide therapy
• Must have written informed consent
• Must be able and willing to comply with study procedures
• \	Must have received prior treatment with radiotherapy (conventional fractionated external beam) and (neo)adjuvant/concurrent chemotherapy (with a temozolomide- or a nitrosurea-based containing )regimen for GBM

You may not qualify if:

• Must not have received prior treatment (except for surgical debulking) of first relapse (progression or recurrence) of GBM
• Must not have received prior treatment with another topoisomerase-I inhibitor (e.g. irinotecan, topotecan, rubitecan)
• Must not have had radiosurgery or radiotherapy within 1 month prior to randomization
• Must not have had prior brachytherapy or chemotherapy wafer implantation
• Must not have had prior high-dose chemotherapy with bone marrow or stem cell support
• Must not receive concomitant treatment with any other investigational agent or anti-cancer treatment during the study
• Must not be currently enrolled in another therapeutic clinical trial for the treatment of GBM
• Must not currently (or in the past 5 years) have other malignancies (except for adequately treated basal cell or squamous cell skin cancer or non-invasive cervical cancer)
• Must not have any of the following in the past 6 months: myocardial infarction (heart attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (stroke), or transient ischemic attack (TIA)
• Must not have had any of the following in the past 2 months: pulmonary embolus (blood clot in lungs), deep venous thrombosis (blood clot in veins), or other significant thromboembolic event
• Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or higher (NCI Common Toxicity Criteria, Version 2.0)
• Must not have known human immunodeficiency virus (HIV) infection
• Must not be pregnant or breastfeeding. Patients (male and female) must be surgically sterile (or postmenopausal for females) or must agree to use effective contraception during the period of study treatment
• Must not be inappropriate for entry into the study, in the judgment of the investigator

Sponsors & Collaborators

• Pfizer: lead

Study Sites (52)

Pfizer Investigational Site

Phoenix, Arizona, United States

Location

Pfizer Investigational Site

Little Rock, Arkansas, United States

Location

Pfizer Investigational Site

New Haven, Connecticut, United States

Location

Pfizer Investigational Site

Orlando, Florida, United States

Location

Pfizer Investigational Site

Atlanta, Georgia, United States

Location

Pfizer Investigational Site

Chicago, Illinois, United States

Location

Pfizer Investigational Site

Evanston, Illinois, United States

Location

Pfizer Investigational Site

Edgewood, Kentucky, United States

Location

Pfizer Investigational Site

Edgweood, Kentucky, United States

Location

Pfizer Investigational Site

Lexington, Kentucky, United States

Location

Pfizer Investigational Site

Boston, Massachusetts, United States

Location

Pfizer Investigational Site

Lebanon, New Hampshire, United States

Location

Pfizer Investigational Site

Edison, New Jersey, United States

Location

Pfizer Investigational Site

Summit, New Jersey, United States

Location

Pfizer Investigational Site

Cincinnati, Ohio, United States

Location

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Location

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Location

Pfizer Investigational Site

Dallas, Texas, United States

Location

Pfizer Investigational Site

Charlottesville, Virginia, United States

Location

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Location

Pfizer Investigational Site

East Bentleigh, Victoria, Australia

Location

Pfizer Investigational Site

Clayton, Australia

Location

Pfizer Investigational Site

Graz, Austria

Location

Pfizer Investigational Site

Vienna, Austria

Location

Pfizer Investigational Site

Calgary, Alberta, Canada

Location

Pfizer Investigational Site

Vancouver, British Columbia, Canada

Location

Pfizer Investigational Site

Winnipeg, Manitoba, Canada

Location

Pfizer Investigational Site

Moncton, New Brunswick, Canada

Location

Pfizer Investigational Site

Halifax, Nova Scotia, Canada

Location

Pfizer Investigational Site

Hamilton, Ontario, Canada

Location

Pfizer Investigational Site

Ottawa, Ontario, Canada

Location

Pfizer Investigational Site

Toronto, Ontario, Canada

Location

Pfizer Investigational Site

Split, Croatia

Location

Pfizer Investigational Site

Zagreb, Croatia

Location

Pfizer Investigational Site

Hradec Králové, Czechia

Location

Pfizer Investigational Site

Prague, Czechia

Location

Pfizer Investigational Site

Lyon, France

Location

Pfizer Investigational Site

Nantes Saint Herblain, France

Location

Pfizer Investigational Site

Berlin, Germany

Location

Pfizer Investigational Site

Mainz, Germany

Location

Pfizer Investigational Site

Regensburg, Germany

Location

Pfizer Investigational Site

Tübingen, Germany

Location

Pfizer Investigational Site

Bangalore, India

Location

Pfizer Investigational Site

Bologna, Italy

Location

Pfizer Investigational Site

Padua, Italy

Location

Pfizer Investigational Site

Moscow, Russia

Location

Pfizer Investigational Site

Cape Town, South Africa

Location

Pfizer Investigational Site

Pretoria, South Africa

Location

Pfizer Investigational Site

Badalona, Spain

Location

Pfizer Investigational Site

L'Hospitalet de Llobregat, Spain

Location

Pfizer Investigational Site

Oviedo, Spain

Location

Pfizer Investigational Site

Location

MeSH Terms

Conditions

Glioblastoma

Interventions

edotecarin; Temozolomide; Carmustine; Lomustine

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nitrosourea Compounds; Urea; Amides; Nitroso Compounds

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: September 12, 2003
• First Posted: September 16, 2003
• Study Start: August 1, 2003
• Study Completion: March 1, 2006
• Last Updated: April 1, 2008

Record last verified: 2008-03

Locations

US (19); DE (4); AU (2); RU (1); ES (3); IT (2); IN (1); CR (2); ZA (2); CZ (2); FR (2); CA (8)